Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1956 1
1957 2
1964 1
1966 1
1968 2
1973 1
1974 2
1976 1
1977 1
1979 2
1980 3
1981 2
1982 1
1983 1
1984 1
1985 1
1986 1
1987 4
1988 3
1989 6
1990 5
1991 1
1993 4
1994 3
1995 1
1996 2
1997 1
1998 2
1999 2
2000 3
2002 5
2003 2
2004 1
2005 1
2006 2
2007 3
2008 1
2009 2
2010 5
2011 9
2012 7
2013 11
2014 6
2015 8
2016 6
2017 11
2018 4
2019 7
2020 4
2021 3
2022 2
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Ge Qin W, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt SA, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Blood. 2024 May 10:blood.2023023557. doi: 10.1182/blood.2023023557. Online ahead of print. Blood. 2024. PMID: 38728378
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz M, Mailankody S, Tan C, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt S, Usmani SZ, Firestone RS. Howard AJ, et al. Among authors: firestone rs. Blood Adv. 2024 Jun 25;8(12):3246-3253. doi: 10.1182/bloodadvances.2024012871. Blood Adv. 2024. PMID: 38621239
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Hamadeh IS, Shekarkhand T, Rueda C, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt S, Usmani SZ, Tan CR. Hamadeh IS, et al. Among authors: firestone rs. Blood Adv. 2024 Jun 25;8(12):3038-3044. doi: 10.1182/bloodadvances.2024012724. Blood Adv. 2024. PMID: 38598713
Current use of CAR T cells to treat multiple myeloma.
Firestone RS, Mailankody S. Firestone RS, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):340-347. doi: 10.1182/hematology.2023000434. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066841 Review.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. Firestone RS, et al. Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225. Blood Adv. 2024. PMID: 37878808 Free PMC article.
164 results